Welcome to Dermbits! Watch short videos of KOLs answering your questionsSee all conditionsAcneActinic KeratosisAestheticsAlopeciaAtopic DermatitisConnective Tissue DiseasesCOVID-19Cutaneous MelanomaEczemaGeneralized Pustular Psoriasis (GPP)Hair and NailsHidradenitis SuppurativaJAK InhibitorsNB-UVBPigmentary DisordersPsoriasisPsoriatic ArthritisRosaceaSkin CancerSunscreenTopical TherapiesVitiligoWarts And MolluscumPsoriasisAre there specific patient populations who are at higher risk for adverse effects from ixekizumab?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisWhat are the considerations for using ixekizumab in patients with a history of serious infections?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisDoes patient weight impact the dosing and efficacy of ixekizumab?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisWhat strategies can be used to taper ixekizumab in patients with sustained remission?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisCan ixekizumab therapy lead to sustained remission or disease modification in patients with psoriasis?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisShould ixekizumab be used as a monotherapy, or can it be used concomitantly with other therapies?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisAre there any special considerations for transitioning patients with psoriasis from other biologic agents to ixekizumab?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisWhat factors contribute to the progression from mild to severe psoriasis?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisHow can early intervention impact the long-term course of psoriasis?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisHow can dermatologists encourage a holistic approach to psoriasis treatment, including lifestyle modifications and mental health support?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisHow does ixekizumab impact cardiovascular risk factors in patients with psoriasis?Featuring Tina Bhutani, MD, MASPsoriasisWhat are the long-term outcomes of ixekizumab therapy in terms of durability of response and maintenance of skin clearance?Featuring Tina Bhutani, MD, MASPsoriasisHow does ixekizumab influence the risk of infections in patients with psoriasis?Featuring Tina Bhutani, MD, MASPsoriasisIs there any benefit to extending the dosing interval of ixekizumab in patients with stable psoriasis?Featuring Tina Bhutani, MD, MASPsoriasisIs there any evidence to suggest ixekizumab is more effective in certain psoriasis phenotypes or patient subgroups?Featuring Tina Bhutani, MD, MASPsoriasisWhat lifestyle modifications should be recommended to patients receiving ixekizumab?Featuring Tina Bhutani, MD, MASPsoriasisWhat is the recommended monitoring for patients with psoriasis receiving ixekizumab?Featuring Tina Bhutani, MD, MASPsoriasisWhat is the role of biopsy in confirming a diagnosis of psoriasis?Featuring Tina Bhutani, MD, MASPsoriasisWhat role do patient preferences play in selecting a psoriasis treatment regimen?Featuring Tina Bhutani, MD, MASPsoriasisHow do you address patient concerns about the long-term use of biologics?Featuring Tina Bhutani, MD, MASPsoriasisWhat are the most common side effects associated with ixekizumab in long-term use?Featuring Laura Ferris, MD, PhDPsoriasisHow does ixekizumab's mechanism of action differ from that of other biologics used for psoriasis?Featuring Laura Ferris, MD, PhDPsoriasisHow does the recommended dosing regimen for ixekizumab compare to those of other biologics for psoriasis?Featuring Laura Ferris, MD, PhDPsoriasisCan ixekizumab be used in combination with topical treatments, and if so, what is the recommended approach?Featuring Laura Ferris, MD, PhDPsoriasisIs there a need for loading doses when initiating ixekizumab therapy?Featuring Laura Ferris, MD, PhDPsoriasisHow should dermatologists approach ixekizumab therapy in patients planning to conceive?Featuring Laura Ferris, MD, PhDPsoriasisWhat considerations should be made for elderly patients starting ixekizumab?Featuring Laura Ferris, MD, PhDPsoriasisWhat are the considerations for using ixekizumab in patients with comorbidities such as diabetes or cardiovascular disease?Featuring Laura Ferris, MD, PhDPsoriasisHow should dermatologists address concerns about injection-site reactions in patients starting ixekizumab?Featuring Laura Ferris, MD, PhDPsoriasisHow should psoriasis be managed in patients with a history of liver disease?Featuring Laura Ferris, MD, PhDPsoriasisWhat monitoring is essential for patients on long-term systemic psoriasis therapies?Featuring Laura Ferris, MD, PhDPsoriasisWhat strategies can be used to improve patient adherence in psoriasis treatment regimens?Featuring Laura Ferris, MD, PhDPsoriasisHow does the safety profile of ixekizumab compare to other IL-17 inhibitors?Featuring Saakshi Khattri , MDPsoriasisHow soon can patients on ixekizumab for psoriasis expect to see results?Featuring Saakshi Khattri , MDPsoriasisCan ixekizumab be safely used in patients with comorbidities like hepatitis B or tuberculosis?Featuring Saakshi Khattri , MDPsoriasisWho is the ideal patient for ixekizumab, and are there any notable exclusions?Featuring Saakshi Khattri , MDPsoriasisWhat patient education points are important to convey to patients starting ixekizumab?Featuring Saakshi Khattri , MDPsoriasisAre there any dose adjustments needed for patients with renal or hepatic impairment when using ixekizumab?Featuring Saakshi Khattri , MDPsoriasisAre there any head-to-head studies comparing ixekizumab to other biologics?Featuring Saakshi Khattri , MDPsoriasisDo patients with nail and scalp psoriasis have a greater risk of developing psoriatic arthritis?Featuring Saakshi Khattri , MDPsoriasisWhat are the most important factors to consider when selecting a first-line biologic for patients with psoriasis?Featuring Saakshi Khattri , MDPsoriasisHow do you manage patients with psoriasis with concurrent inflammatory bowel disease?Featuring Saakshi Khattri , MDPsoriasisWhat are the most common adverse reactions seen with ixekizumab?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisWhat is the dosing regimen for ixekizumab?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisWhat factors should be considered when determining optimal treatment duration for ixekizumab in patients with psoriasis?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisIs ixekizumab safe for use in pediatric populations?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisWhat is the mechanism of action of ixekizumab?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisWhen do you consider a biologic as a first-line treatment for psoriasis?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisWhat are some common reasons for undertreatment of patients with psoriasis and how can dermatologists address this?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisWhat is your approach when counseling a patient who has experienced multiple treatment failures?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisWhat role does patient education play in improving adherence to psoriasis treatment regimens?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisHow do newer biologic agents like IL-17 inhibitors compare to traditional biologics in psoriasis treatment?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisWhat is the recommended dosing regimen for tapinarof?Featuring Tina Bhutani, MD, MASPsoriasisWho is the ideal patient for tapinarof, and are there any notable exclusions?Featuring Tina Bhutani, MD, MASPsoriasisWhat is the safety profile of tapinarof?Featuring Tina Bhutani, MD, MASPsoriasisWhat is the mechanism of action of tapinarof?Featuring Tina Bhutani, MD, MASPsoriasisWhat should patients expect when they stop treatment with tapinarof?Featuring Tina Bhutani, MD, MASPsoriasisWhat were the primary endpoints of the PSOARING 1 and PSOARING 2 trials for tapinarof?Featuring Tina Bhutani, MD, MASPsoriasisIs tapinarof well tolerated on sensitive skin areas?Featuring Tina Bhutani, MD, MASPsoriasisWhat is the role of the Aryl hydrocarbon receptor in psoriasis and psoriasis management?Featuring Tina Bhutani, MD, MASPsoriasisWhat are the latest advancements in understanding the pathogenesis of psoriasis?Featuring Tina Bhutani, MD, MASPsoriasisHow do lifestyle factors like diet and stress impact your approach to psoriasis management?Featuring Tina Bhutani, MD, MASPsoriasisHow do you counsel patients on quality of life impacts from psoriasis?Featuring Tina Bhutani, MD, MASPsoriasisWhat monitoring is recommended for routine patient management with bimekizumab to assess liver enzyme levels?Featuring April Armstrong, MD, MPHPsoriasisHow does the dosing regimen and speed of response of bimekizumab compare to other biologics for psoriasis?Featuring April Armstrong, MD, MPHPsoriasisIs bimekizumab effective for patients who have failed an IL-17 blocker?Featuring April Armstrong, MD, MPHPsoriasisHas the efficacy of bimekizumab been compared to other psoriasis medications?Featuring April Armstrong, MD, MPHPsoriasisWhat is the long-term safety data for bimekizumab? Featuring April Armstrong, MD, MPHPsoriasisWhat is the risk of suicidal ideation or behavior in patients taking bimekizumab?Featuring April Armstrong, MD, MPHPsoriasisDoes bimekizumab have a boxed warning?Featuring April Armstrong, MD, MPHPsoriasisHow do you approach long-term management of plaque psoriasis?Featuring April Armstrong, MD, MPHPsoriasisWhat are some of the limitations of the current conventional clinical measures used to determine psoriasis severity? Featuring April Armstrong, MD, MPHPsoriasisWhat are some limitations of the older biologics for psoriasis? Featuring April Armstrong, MD, MPHPsoriasisIs there drug monitoring required for bimekizumab?Featuring Mark Lebwohl, MDPsoriasisWhat is the dosing regimen for bimekizumab?Featuring Mark Lebwohl, MDPsoriasisWhat is the mechanism of action of bimekizumab and how does it differ from other systemic psoriasis treatments?Featuring Mark Lebwohl, MDPsoriasisWhat is the safety profile of bimekizumab and what are the most common adverse effects seen so far?Featuring Mark Lebwohl, MDPsoriasisWho is eligible for treatment with bimekizumab? Are there any notable exclusion criteria?Featuring Mark Lebwohl, MDPsoriasisWhat is the recommended dosing regimen for clobetasol propionate cream 0.025%? Featuring Leon Kircik, MDPsoriasisHow does the safety and efficacy of clobetasol propionate cream 0.025% compare with the 0.05% cream?Featuring Leon Kircik, MDPsoriasisWhat makes the formulation of clobetasol propionate cream 0.025% unique?Featuring Leon Kircik, MDPsoriasisWhat is the recommended dosing regimen for betamethasone dipropionate spray 0.05%?Featuring Leon Kircik, MDPsoriasisWhat are some of the benefits of a spray treatment like betamethasone dipropionate spray 0.05% for plaque psoriasis?Featuring Leon Kircik, MDPsoriasisWhat areas of the body does betamethasone dipropionate spray 0.05% work best on?Featuring Leon Kircik, MDPsoriasisHow important is the delivery vehicle when selecting a topical treatment for psoriasis?Featuring Leon Kircik, MDPsoriasisHow do you counsel patients on the importance of adherence when prescribing a topical treatment for psoriasis?Featuring Leon Kircik, MDPsoriasisDo issues of accessibility affect your approach when considering treatment options for plaque psoriasis?Featuring Leon Kircik, MDPsoriasisWhat place do topicals have in the psoriasis treatment landscape now that the range of therapeutic options has expanded dramatically?Featuring Leon Kircik, MDPsoriasisHow do you foresee the availability of nonsteroidal topical options contributing to the standard of care for plaque psoriasis?Featuring Jennifer Soung, MDPsoriasisWhat are some of the limitations of topical steroids with respect to management of plaque psoriasis?Featuring Jennifer Soung, MDPsoriasisWhat are important considerations when treating plaque psoriasis in sensitive areas such as the face, folds, and genitals?Featuring Jennifer Soung, MDPsoriasisWhat limitations of other topical therapies does roflumilast address for patients with plaque psoriasis?Featuring Jennifer Soung, MDPsoriasisWhat clinical findings strike you most when choosing topical roflumilast for patients with plaque psoriasis?Featuring Jennifer Soung, MDPsoriasisCan you explain the significance of roflumilast’s indication being inclusive of intertriginous areas with plaque psoriasis?Featuring Jennifer Soung, MDPsoriasisCan topical roflumilast be used in combination with systemic therapies?Featuring Jennifer Soung, MDPsoriasisIs topical roflumilast safe and effective for long-term use?Featuring Jennifer Soung, MDPsoriasisHow would you describe the formulation/vehicle for topical roflumilast?Featuring Jennifer Soung, MDPsoriasisNow that there are more options to treat psoriasis, how do you choose when to use roflumilast?Featuring Jennifer Soung, MDPsoriasisWhat is new and exciting for treating pediatric patients with plaque psoriasis?Featuring Jennifer Soung, MDPsoriasisWith all of the new treatments for psoriasis that have been approved in recent years, is there still an unmet need?Featuring Mark Lebwohl, MDPsoriasisCan you speak to the efficacy of bimekizumab from the three pivotal head-to-head trials?Featuring Mark Lebwohl, MDPsoriasisHow quickly does bimekizumab start working?Featuring Mark Lebwohl, MDPsoriasisRegarding oral candidiasis, how has this been managed and has it required discontinuation of the medication? Featuring Mark Lebwohl, MDPsoriasisAre there any support programs to help patients access bimekizumab?Featuring Mark Lebwohl, MDPsoriasisWhat are some patient examples you’ve had success with using topical roflumilast?Featuring Saakshi Khattri , MDPsoriasisHow does the formulation of roflumilast differ from other topicals?Featuring Saakshi Khattri , MDPsoriasisWhat properties of roflumilast allow it to follow a once-daily dosing regimen?Featuring Saakshi Khattri , MDPsoriasisWhat is the mechanism of action of roflumilast? Featuring Saakshi Khattri , MDPsoriasisDo patients using roflumilast experience stinging and burning?Featuring Saakshi Khattri , MDPsoriasisAre there any limitations on duration of use with roflumilast? Featuring Saakshi Khattri , MDPsoriasisWho is the ideal patient for roflumilast?Featuring Saakshi Khattri , MDPsoriasisWhat does the long-term safety and durability profile look like for roflumilast? Featuring Saakshi Khattri , MDPsoriasisDoes roflumilast continue to be effective over a long period of time? Featuring Saakshi Khattri , MDPsoriasisHas the emergence of new topical options affected the course of treatment you select for your patients?Featuring Saakshi Khattri , MDPsoriasisWhat are the advantages of topical therapy as monotherapy over systemic therapy for plaque psoriasis? Featuring Saakshi Khattri , MDPsoriasisHow have the emergence of nonsteroidal topical options in recent years impacted your practice? Featuring Saakshi Khattri , MDPsoriasisHow quickly do patients experience clearance results with topical roflumilast?Featuring Peter Lio, MDPsoriasisHow would you describe the overall tolerability of topical roflumilast? Featuring Peter Lio, MDPsoriasisWhat is the long-term safety and efficacy data of topical roflumilast? Featuring Peter Lio, MDPsoriasisHow has topical roflumilast simplified the way you consult patients with plaque psoriasis? Featuring Peter Lio, MDPsoriasisHow would you present the product profile of topical roflumilast to HCP colleagues who are reluctant due to poor prior experience with other PDE4 inhibitors?Featuring Peter Lio, MDPsoriasisWhen it comes to treating thicker plaques on hands and feet, why should you consider Zoryve instead of steroids?Featuring Peter Lio, MDPsoriasisWhat are your thoughts on topical roflumilast as becoming standard of care and gradual shifting away from topical corticosteroids?Featuring Peter Lio, MDPsoriasisHow do you approach management of plaque psoriasis in challenging sensitive areas?Featuring Peter Lio, MDPsoriasisHow important is inclusion of younger ages - adolescent or pediatric – when it comes to indication for plaque psoriasis treatments?Featuring Peter Lio, MDPsoriasisWhen augmenting oral and/or biologic therapy with a topical, what are some of the considerations you think through?Featuring Peter Lio, MDPsoriasisWhat ingredients do you like to see in the products you use to treat plaque psoriasis?Featuring Joseph Pietrangelo, MDPsoriasisHow important are vehicles in topical Plaque Psoriasis therapy? Featuring Joseph Pietrangelo, MDPsoriasisWhat common ingredients in topical therapies for plaque psoriasis may cause irritation for your patients?Featuring Joseph Pietrangelo, MDPsoriasisShould we really care about systemic safety when treating Plaque Psoriasis with topical therapies? Featuring Joseph Pietrangelo, MDPsoriasisHow important is continuity of care for topical plaque psoriasis therapy? Featuring Joseph Pietrangelo, MDPsoriasisHow much time does your staff have to spend gaining patient access to medication for plaque psoriasis? Featuring Joseph Pietrangelo, MDPsoriasisHow do you utilize product samples in plaque psoriasis? Featuring Joseph Pietrangelo, MDPsoriasisHow do access, tolerability and efficacy improve compliance? Featuring Joseph Pietrangelo, MDPsoriasisWhich patients fit the profile for combination therapy of Biologics and topical treatment in Plaque Psoriasis?Featuring Joseph Pietrangelo, MDPsoriasisHow do you address compliance with your patients in topical treatment of plaque psoriasis?Featuring Joseph Pietrangelo, MDPsoriasisWhat are some clinical tips to help identify and/or uncover whether patients have intertriginous psoriasis so that these areas are not overlooked or avoided?Featuring Laura Ferris, MD, PhDPsoriasisIs there any evidence that patients can build tolerance to topical roflumilast?Featuring Laura Ferris, MD, PhDPsoriasisHow can topical roflumilast impact quality of life in patients with psoriasis?Featuring Laura Ferris, MD, PhDPsoriasisWhat advantages does topical roflumilast have over other topical treatments for psoriasis?Featuring Laura Ferris, MD, PhDPsoriasisCan topical roflumilast be used as a first-line agent? Are all disease severities appropriate for topical roflumilast?Featuring Laura Ferris, MD, PhDPsoriasisDoes topical roflumilast have data that shows reduction of itch?Featuring Laura Ferris, MD, PhDPsoriasisWhich psoriasis symptoms are most burdensome for patients?Featuring Laura Ferris, MD, PhDPsoriasisHow durable is the efficacy of topical roflumilast for the long-term?Featuring Laura Ferris, MD, PhDPsoriasisWhat excites you most about the approval of topical roflumilast?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisWhich patients may benefit the most from topical roflumilast?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisHow effective is topical roflumilast at treating sensitive areas like the face, genitalia, and intertriginous psoriasis areas?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisWhat is the mechanism of action of topical roflumilast and how is it different than other PDE4 inhibitors?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisCan topical roflumilast replace topical corticosteroids, or are they meant to be used in tandem?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisWhat is the overall safety and tolerability profile for topical roflumilast?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisDo you augment oral and/or biologic therapy with a topical?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisHow do you determine if a patient is a better candidate for topical treatment vs. an oral or biologic?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisCan topical roflumilast be used for younger patients?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisIs topical roflumilast safe for long-term use?Featuring Raj Chovatiya, MD, PhD, MSCIPsoriasisHow important is the delivery vehicle for topical treatment of psoriasis?Featuring Andrew Alexis, MD, MPHPsoriasisDoes topical roflumilast treat pruritus associated with psoriasis?Featuring Andrew Alexis, MD, MPHPsoriasisDoes topical roflumilast have data that supports its safety and efficacy for long-term use?Featuring Andrew Alexis, MD, MPHPsoriasisThere has been increased emphasis placed on treatment of plaque psoriasis in intertriginous and/or genital areas. How do you approach management of disease in these areas?Featuring Andrew Alexis, MD, MPHPsoriasisHow is roflumilast different than other PDE4 inhibitors?Featuring Andrew Alexis, MD, MPHPsoriasisTopical roflumilast is indicated for patients 12 years and older. What is the significance of this as you think about topical treatment options for patients?Featuring Andrew Alexis, MD, MPHPsoriasisAre there any sensitizing ingredients or irritants in topical roflumilast and does it contain propylene glycol?Featuring Andrew Alexis, MD, MPHPsoriasisDid the Phase 3 pivotal studies for roflumilast specifically evaluate itch reduction?Featuring Andrew Alexis, MD, MPHPsoriasisWhat are the advantages of topical roflumilast over traditional topical corticosteroids in the treatment of psoriasis?Featuring Andrew Alexis, MD, MPHPsoriasisWhat’s your perception of the formulation/cream of topical roflumilast and why does this matter for patients?Featuring Mark Lebwohl, MDPsoriasisWhat is the long-term safety and efficacy data of topical roflumilast?Featuring Mark Lebwohl, MDPsoriasisHow quickly do patients see results with topical roflumilast?Featuring Mark Lebwohl, MDPsoriasisWhat is the overall tolerability of topical roflumilast and what are the most common side effects?Featuring Mark Lebwohl, MDPsoriasisWhich efficacy outcomes for topical roflumilast do you find most compelling and why?Featuring Mark Lebwohl, MDLoad more videos168 of 213Previous pageNext page
